Merck KGaA’s says cancer vaccine safe in study
May 30th, 2009
Merck KGaA’s experimental cancer vaccine Stimuvax proved safe to use in a long-term Phase II study on lung cancer patients, the German drugmaker said on Saturday.
The trial showed that patients’ immune systems did not turn on normal cells, a major concern in new vaccines that are designed to prime the body’s immune system to detect and attack cancer cells.